Brown Capital Management Small-Cap Fund Bets on Krystal Biotech

Brown Capital Management's Small-Cap Fund has included Krystal Biotech (KRYS) shares in its portfolio, signaling confidence in the biotechnology company's resilient revenue stream. Fund managers made this investment decision based on Krystal Biotech's stable income from existing products and its future growth potential. The company's expertise in gene therapies, particularly its advancements in treatments for rare diseases, stands out. Krystal Biotech's revenue resilience is supported by market acceptance of its current products and ongoing R&D efforts. Brown Capital Management believes these factors enhance the company's long-term value creation capacity. The fund focuses on small-cap companies, pursuing a strategy of investing in high-growth but lesser-known firms. Analysts note that Krystal Biotech's existing product portfolio, along with new treatments in development, could expand the company's revenue base. However, regulatory risks and competitive pressures in the biotechnology sector are factors investors should monitor. Brown Capital Management's investment reflects its confidence in the company's core strengths. This is not investment advice.